Increased numbers of requests for serological investigation of coeliac disease, and a local trend to request both anti-gliadin antibodies (AGA) and antiendomysium antibodies (AEA) simultaneously, resulted in cost pressures that prompted a review of our practice. Serology results from all patients (771 children, 511 adults) investigated for coeliac disease over a 3-year period were compared with small intestine histology where available. IgG AGA and IgA AGA were measured by enzyme-linked immunosorbent assay (in-house), IgA AEA by immunofluorescence (send-away contract). Overall diagnostic performance was as follows: AGA sensitivity 84%, specificity 88%, positive predictive value (PPV) 24%, negative predictive value (NPV) 99%; AEA sensitivity 88%, specificity 97%, PPV 65%, NPV 99%.
Laboratory directors will be familiar with the relentless pressure to provide greater numbers of increasingly sophisticated and expensive investigations against a background of resource constraints. This is exemplified by the increased numbers of requests for the serological investigation of coeliac disease that our laboratory has received recently. This trend has followed the recognition that coeliac disease is more common than was previously thought and may affect 1 in 200 individuals. 1 Furthermore, a recent study has suggested that under-diagnosis and misdiagnosis of coeliac disease are common in general practice and advocates serological screening for coeliac disease in patients with anaemia or in those who are chronically tired, especially if there is a positive family history.!
The diagnosis of coeliac disease is made after observing the characteristic pathological appearance on small intestine biopsy and achieving complete clinical and histological remission on a gluten-free diet. 3 However, the appeal of a Correspondence: Ms A Bowron. E-mail: Ann.Bowron@ubht.swest.nhs.uk diagnostic blood test, which avoids the invasive biopsy, has led to the development of a variety of serological tests based on the detection of serum antibodies to gut muscle connective tissue and/or to wheat protein. IgA anti-endomysium antibodies (AEA) and IgA and IgG anti-gliadin antibodies (AGA) are used extensively.r" and use of IgA anti-tissue transglutaminase antibodies (AtTGA) has recently been described for coeliac disease.t-'" All have advantages and disadvantages. Anti-gliadin antibodies lack specificity since they occur in a variety of inflammatory conditions that allow wheat proteins to leak through the bowel wall and stimulate antibody production. Anti-endomysium antibodies are the most specific of the serological markers but, in our (typical) clinical biochemistry laboratory, are approximately five times more expensive than AGAs since the test requires referral to a specialist immunology laboratory. They may also be found in noncoeliac inflammatory gut disease. Use of AtTGAs has not yet been fully evaluated in a clinical setting. In addition, coeliac disease patients are more likely to have IgA deficiency, which limits the use of IgA markers. 11 As a consequence of these problems none of the serological markers have been found to have sufficient sensitivity or specificity to be used as a single diagnostic test for coeliac disease.":'?
In our hospital the diagnosis of coeliac disease is made on the basis of a combination of serological investigation with AGA and AEA, and selective biopsy. The number of requests for coeliac serology has risen because of a trend to request both tests on initial clinic visit. The purpose of this study was to evaluate diagnostic performance of AGA and AEA in order to judge whether the greater cost of performing both tests as a first-line screen was justified.
METHODS

Patients
All patients presenting between 1995 and 1998 to the Bristol Royal Infirmary and Bristol Children's hospital in whom AGA/AEA measurements and/or small intestinal biopsy were performed were included in this retrospective study. A total of 1282 patients (771 children aged less than 16 years and 511 adults) were investigated during this period and the results of serological investigations compared with the results of small intestine biopsies (if done). Standard histological criteria were used to establish the diagnosis of coeliac disease.'
Serological markers
Both IgA and IgG AGA were measured by an in-house enzyme-linked immunosorbent assay (ELISA)12 using plastic 96-well plates coated overnight with crude gliadin (Sigma G-3375, Sigma-Aldrich Company Ltd, Dorset, UK). Serum (diluted 1/40 in phosphate-buffered saline) was added and plates incubated for 90 min before washing and the addition of IgA and IgG rabbit anti-human polyclonal antisera (DAKO Ltd, Buckinghamshire, UK) conjugated with alkaline phosphatase. The assay was calibrated against a commercial method (Pharmacia and Upjohn Ltd, Berkshire, UK). A positive result was defined as an IgA or IgG AGA concentration greater than 25 U/mL. Results are in consensus with the relevant UK National External Quality Assurance Scheme.
Measurements of IgA AEA were made by indirect immunofluorescence, using monkey oesophagus as substrate, by The Protein Reference Unit, Department of Immunology, Sheffield.
Total IgA was measured in all patients using goat anti-human IgA antisera (Atlantic Antibodies, Dia Soren, Berkshire, UK) on a Kone Pro Analyser (Labmedics Ltd, Stockport, UK).
Calculations
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of AGA and AEA were calculated. 13 Patients were classified as having a diagnosis of coeliac disease if they had characteristic histological changes on small intestine biopsy.' Patients whose biopsy was negative or who did not have a biopsy performed were classified as not having coeliac disease.
RESULTS
Anti-gliadin antibody (IgA and IgG) results were available for 1223 patients and AEA results for 566. Both tests were performed on 525 patients. A total of 180 patients were positive by AGA (IgA and/or IgG) and 46 by AEA. Coeliac disease was diagnosed in 75 patients on the basis of biopsy. Details of the serological and histological findings are shown in Table I . Results of the serological investigations were compared with biopsy results and the diagnostic performance of AGA and AEA calculated (see Tables 2 and 3) .
None of the false negative AEA or AGA results were from patients with IgA deficiency.
DISCUSSION
We have evaluated the diagnostic performance of AGA and AEA in the clinical setting. Most previous studiesr '? have defined coeliac disease by criteria based on small intestine biopsy and Used this to calculate the diagnostic performance of serological markers. Since all patients in these studies necessarily had a biopsy, there is a selection bias that may introduce inaccuracy into the assessment of serological marker performance in the normal clinical setting (where not all patients have had a biopsy).
In order to assess accurately the performance of these serological markers it would be necessary for all patients with a putative diagnosis of coeliac disease to undergo a small bowel biopsy before and after withdrawal of gluten. This is
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neither ethical nor practical and therefore all calculations of assay performance are imperfect. Our assessment of AGA and AEA diagnostic performance included all patients investigated for coeliac disease by our (typical) chemical pathology laboratory. We calculated diagnostic performance by classifying all patients who had a positive small intestine biopsy as positive for coeliac disease and all those who did not (i.e. those whose biopsy was negative, or who did not undergo biopsy) as not having coeliac disease. These results are shown in Table 2 .
However, occasionally a patient may have positive serology but not undergo small intestine biopsy (for example, if the patient is unwilling). Although these patients fail to have a biopsy performed, a diagnosis of coeliac disease cannot be excluded. We therefore recalculated the diagnostic performance of AGA and AEA, excluding those patients who did not undergo biopsy (see Table 3 ).
When selecting a test for first-line screening it is important to have a high NPV (the proportion of patients with negative results who are diseasefree).'? This avoids excluding a patient with the disease from further investigation due to a false negative result. In both methods of calculation of diagnostic performance AGA and AEA showed over 99% NPV; they are therefore equally suitable first-line tests. However, as AGA is the cheaper test we have selected it for first-line investigation. The AGA test has a low PPV and lower specificity for coeliac disease, therefore follow-up with AEA (which has at least 97% specificity) when AGA is positive improves diagnostic performance of these tests.
Inevitably, this judgement is based on pragmatism. We accept that there is no single diagnostic procedure that is appropriate for all patients presenting to a clinician with symptoms that may result from coeliac disease. We are also aware of the resource-consuming tendency for send-away tests to increase year on year and believe that this affects most clinical biochemistry departments; in this department, send-away tests increased by 19% between 1998 and 1999. Furthermore, the measurement of AGA is feasible for most clinical biochemistry laboratories, unlike AEA measurement which is not easily automatable and requires experience in immunofluorescence techniques. The financial cost of increased numbers of send-away tests, compounded by the new postal regulations, together with the delayed availability of results, lead us to examine critically the advantages of AEA compared with AGA for the diagnosis of coeliac disease in our laboratory (which we believe is representative of most medium-sized laboratories).
It has been proposed that IgA AEA be used as a single screening test for coeliac disease" but we believe that the high cost, as well as the risk of false negative results in patients with IgA deficiency, rule this out.
Based on these findings we propose a stepwise approach to the investigation of coeliac disease. First, IgA and IgG AGA should be measured. If either or both are positive, this should be followed by measurement of IgA AEA which, if positive, may lead to biopsy. If clinical suspicion is high AEA may be measured in addition to AGA, even if the latter is normal. Total IgA should be measured in subjects with elevated IgG AGA and normal IgA AGA to exclude IgA deficiency, which would potentially cause false negative AEA results.
No laboratory test or combination of tests shows 100% sensitivity or specificity for the identification of coeliac disease, and occasionally even the biopsy histology may be misleading." However, the pragmatic approach that we advocate of an initial screen by serum AGAs, followed by AEA and then histology where appropriate, has the advantage of being costeffective and minimizes the need for small intestine biopsies. We estimate that this laboratory will make cost savings of at least £5000 per year by the introduction of this strategy.
